Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M. Albert NL, et al. Among authors: ellingson bm. Lancet Oncol. 2024 Jan;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. Lancet Oncol. 2024. PMID: 38181810 Review.
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB, Rosenthal MA, Hovey EJ, Ellingson BM, Tognela A, Gan HK, Wheeler H, Back M, McDonald KL, Long A, Cuff K, Begbie S, Gedye C, Mislang A, Le H, Johnson MO, Kong BY, Simes JR, Lwin Z, Khasraw M. Sim HW, et al. Among authors: ellingson bm. Neurooncol Adv. 2023 Sep 22;5(1):vdad124. doi: 10.1093/noajnl/vdad124. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37841696 Free PMC article.
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Everson RG, et al. Among authors: ellingson bm. Nat Commun. 2024 May 8;15(1):3882. doi: 10.1038/s41467-024-48073-y. Nat Commun. 2024. PMID: 38719809 Free PMC article. Clinical Trial.
Single-nucleus expression characterization of non-enhancing region of recurrent high-grade glioma.
Patel KS, Tessema KK, Kawaguchi R, Dudley L, Alvarado AG, Muthukrishnan SD, Perryman T, Hagiwara A, Swarup V, Liau LM, Wang AC, Yong W, Geschwind DH, Nakano I, Goldman SA, Everson RG, Ellingson BM, Kornblum HI. Patel KS, et al. Among authors: ellingson bm. Neurooncol Adv. 2024 Jan 25;6(1):vdae005. doi: 10.1093/noajnl/vdae005. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38616896 Free PMC article.
Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast Enhancement.
Bobholz SA, Lowman AK, Connelly JM, Duenweg SR, Winiarz A, Nath B, Kyereme F, Brehler M, Bukowy J, Coss D, Lupo JM, Phillips JJ, Ellingson BM, Krucoff MO, Mueller WM, Banerjee A, LaViolette PS. Bobholz SA, et al. Among authors: ellingson bm. Neurosurgery. 2024 Mar 19. doi: 10.1227/neu.0000000000002898. Online ahead of print. Neurosurgery. 2024. PMID: 38501824
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
Schreck KC, Strowd RE, Nabors LB, Ellingson BM, Chang M, Tan SK, Abdullaev Z, Turakulov R, Aldape K, Danda N, Desideri S, Fisher J, Iacoboni M, Surakus T, Rudek MA, Bettegowda C, Grossman SA, Ye X. Schreck KC, et al. Among authors: ellingson bm. Clin Cancer Res. 2024 May 15;30(10):2048-2056. doi: 10.1158/1078-0432.CCR-23-3241. Clin Cancer Res. 2024. PMID: 38446982 Clinical Trial.
273 results